GSK
PUTS ▼GSK plc
$51.69
-0.73%delayed
News – · Trend ▼ · below put trigger ▼
Expected move (1d)
▼ $50.38to$53.00 ▲
ATR ±$1.31 (+2.53%)Implied ±$1.50 (+2.90%)
Entry Reference
Price / prev close$51.69 / $52.07
Day range$51.38 – $51.98
52-wk range$36.75 – $61.70(60%)
Volume vs avg0.99×
ATR (14d)$1.31
MA 8 / 21$51.94 / $52.08
MA 50 / 200$51.68 / $51.60
Call ▲ / Put ▼ trigger$52.38 / $51.76
+1 / +2 ATR$53.00 / $54.30
-1 / -2 ATR$50.38 / $49.08
Support: 51.55 50.43 49.89
Resistance: 52.11 53.45 54.29
Near-the-money contracts
exp 2026-08-07Calls
| Strike | Mark | IV | Δ | θ/day | OI |
|---|---|---|---|---|---|
| 51 | $1.30 | 38% | 0.63 | -0.08 | 19 |
| 52 | $0.65 | 33% | 0.46 | -0.08 | 30 |
| 53 | $0.30 | 31% | 0.27 | -0.06 | 180 |
| 54 | $0.13 | 32% | 0.15 | -0.04 | 406 |
| 55 | $0.11 | 37% | 0.10 | -0.04 | 178 |
| 56 | $0.05 | 40% | 0.06 | -0.03 | 137 |
Puts
| Strike | Mark | IV | Δ | θ/day | OI |
|---|---|---|---|---|---|
| 48 | $0.05 | 43% | -0.08 | -0.03 | 20 |
| 49 | $0.17 | 46% | -0.16 | -0.06 | 71 |
| 50 | $0.22 | 32% | -0.19 | -0.05 | 87 |
| 51 | $0.38 | 28% | -0.34 | -0.06 | 213 |
| 52 | $0.85 | 31% | -0.55 | -0.07 | 200 |
| 53 | $1.48 | 31% | -0.73 | -0.05 | 214 |
Δ = delta (≈ probability ITM), θ/day = daily time decay, IV = implied vol. Greeks computed via Black-Scholes from Yahoo IV.
Recent news
- Low Growth Viatris Is Due For A Pullback After A Stellar 16-Month Run1d ago
- Watching SCYNEXIS; Shares Trading Higher, Hearing GSK Is Close To Relaunching BREXAFEMME With The Co, FDA Updates BREXAFEMME Label With Pediatric Use Information And Revised Patient Safety Guidance1d ago
- GSK Announces Cabenuva Demonstrates Superiority To Daily Oral Therapy In Adolescents Living With HIV, As Viiv Healthcare Highlights New Long-Acting Injectable Data At AIDS 20264d ago
- GSK plc (GSK) Q2 2026 Earnings Call Transcript4d ago
- GSK Races To Protect Profits Before Its HIV Blockbuster Faces Generic Rivals4d ago
- GSK: Healthy Results, But Limited Stock Upside (Rating Downgrade)5d ago
- GSK Investing £400M To Establish New R&D Center In Cambridge, U.K.5d ago
- Sherwin-Williams Posts Upbeat Q2 Earnings, Joins Itron, Armstrong World And Other Big Stocks Moving Higher On Tuesday5d ago
- GSK plc 2026 Q2 - Results - Earnings Call Presentation5d ago
- Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields5d ago
- GSK FY2031 Revenue expected to be more than $53.204B vs $45.690B Est5d ago
- GSK Affirms FY2026 Adj EPS Guidance of $4.90-$5.00 vs $4.79 Est; Affirms FY2026 Sales Guidance of $44.754B vs $45.690B Est5d ago
Reference data only. Not a recommendation. Greeks and expected-move figures are estimates, not certainties. You confirm all entries and contracts in TradingView and Charles Schwab.